 |
|
|
|
 |
|
|
| Article 1 to 10 out of 43 concerning Generex Biotechnology Corporation
|
-
Generex Announces Enrollment of Over 150 Patients In Phase III Trial of Generex Oral-lyn
(15 Aug 2008)
More than 100 patients currently receiving Generex Oral-lyn; Some Patients for more than Three Months
Generex Biotechnology Corporation announced that it has initiated enrolled over 150 patients in the Company's pivotal Phase III clinical trial of Generex Oral-lyn(TM), its flagship proprietary oral insulin spray product. Of those patients, over 100 ...
-
Generex Establishes Branch Office in Dubai Healthcare City
(29 May 2008)
Generex Biotechnology Corporation announced that it has received a Commercial License from the Government of Dubai, United Arab Emirates. Under the auspices of this Commercial License, Generex has established a branch office in exclusive Dubai ...
-
Generex Biotechnology announces North American initiation of Generex Oral-lynT Phase III Diabetes Study
(09 Apr 2008)
Generex Biotechnology Corporation announced that it has initiated the Phase III protocol in North America for its proprietary buccally-absorbed oral insulin spray product, Generex Oral-lyn, with the commencement of patient screening. The first ...
-
Generex Biotechnology expands its patent portfolio in North & South America
(07 Mar 2008)
Generex Biotechnology Corporation announced that it has received new patents in Canada and Argentina. The Canadian Intellectual Property Office has granted the Company a new patent titled "Mixed Micellar Pharmaceutical Delivery System and Method of ...
-
Generex Biotechnology receives regulatory approval to initiate Phase III clinical trial for Generex Oral-lyn
(25 Jan 2008)
Ministry of Health of the Ukraine approves Phase III protocol GEN084-OL for a number of clinical sites in the Ukraine
Generex Biotechnology Corporation announced that on January 22, 2008 the Ministry of Health of the Ukraine issued an approval letter for the conduct of a Phase III clinical trial protocol for Generex Oral-lyn at eight clinical sites located in the ...
-
Generex Biotechnology receives approval from the Ministry of Health of the United Arab Emirates to sell Generex Oral-lyn T
(13 Dec 2007)
Imperial College London Diabetes Centre receives approval to sell to patients through the diabetes centre in Abu Dhabi, United Arab Emirates
Generex Biotechnology Corporation announced that the Ministry of Health of the United Arab Emirates, Drugs Control Department has issued a non-objection letter to the Imperial College London Diabetes Centre to import Generex Oral-lyn, Generex's ...
-
Generex Biotechnology to collaborate with Rochester University on pandemic avian influenza vaccine
(24 Aug 2007)
Generex Biotechnology Corporation announced that its wholly-owned immunotherapy subsidiary, Antigen Express, Inc., has entered into an agreement with the University of Rochester as part of the Antigen Express efforts to develop a novel vaccine ...
-
Generex Biotechnology Corporation announces expansion of retail chains
(30 Jul 2007)
Generex Biotechnology Corporation announced that the number of retail chains in Canada and the United States that are presently carrying its proprietary Glucose RapidSpray T product has expanded. The latest addition to the retail chains have been a ...
-
Generex Biotechnology to Initiate Phase III Clinical Trial of Generex Oral-lynT in 2007 Third Quarter
(28 Jun 2007)
Company to Commence Patient Dosing by Year-end
Generex Biotechnology Corporation announced that the Company is preparing to commence a Phase III clinical trial of Generex Oral-lyn, the Company's proprietary oral insulin spray product. The Company has been establishing regulatory and clinical ...
-
Generex Biotechnology Granted Patents in Canada and Mexico
(24 Apr 2007)
Company Expands North American Drug Delivery Platform Patent Portfolio
Generex Biotechnology Corporation announced that it has expanded its patent portfolio with newly issued patents in Canada and Mexico issued by the Canadian Intellectual Property Office and the Mexican Institute of Intellectual Property, ...
Additional information
Generex Biotechnology Corporation
Toronto, Canada
Company
|
|
|
|
|
|
Top
